October 21, 2025 | Jennifer Gonzales
The University of Maryland School of Medicine received a $5.5 million endowment from the John C. Martin Foundation to the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM). This sizeable award inaugurates John C Martin Lectureship and Distinguished Chair , the first endowed chair of its kind in this discipline, and one of the largest endowments in IHV’s history.
The John C. Martin Distinguished Chair will be awarded to a senior faculty member of the Institute whose work exemplifies transformative contributions to virology. The endowed will advance the Institute’s mission by supporting research in new discoveries, promoting public private partnerships, implementation research, global outreach to reduce the burden of viral diseases, and promoting education in translational research for fellows in virology.
Additionally, as part of this historic gift, the Institute will establish the John C. Martin Lectureship at the University of Maryland, Baltimore (UMB). This lecture series will bring together leaders in virology and translational medicine to discuss research and will be open to faculty, students and the scientific community.
“John C Martin was a visionary CEO of Gilead Sciences and an advocate of facilitating access to life saving antivirals to everyone affected with the disease in the world,” said Shyam Kottilil, MD, PhD, interim director of IHV. “He was an avid promoter of the work performed at the Institute of Human Virology. It is only most appropriate that John C Martin Foundation decided to honor John by endowing a distinguished professorship chair and an annual lectureship in his name at the institute. This endowment will carry on John’s life mission in fostering virology research at the Institute.”
John C. Martin, PhD, former Chairman and Chief Executive Officer of Gilead Sciences Inc., was a globally recognized scientist and executive whose vision and leadership at Gilead Sciences transformed HIV/AIDS treatment and other viral diseases. His efforts resulted in the development and worldwide distribution of life-saving antiviral therapies that continue to improve millions of lives. Dr. Martin, a long-time friend of the Institute, interacted with IHV leadership very closely and advised many faculty on various research projects. Dr. Martin was honored by the Institute with the Lifetime Achievement Award in 2014 and was the IHV Annual Marlene and Stewart Greenebaum lecturer in 2017. He continued to serve as an advisor and champion for the Institute’s mission until his passing in 2021.
Founded in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, the Institute of Human Virology is home to some of the most globally recognized and world-renowned experts in the field of human virology. Most notable among these diseases is HIV/AIDS.
IHV has previously been the beneficiary of other lucrative philanthropic gifts including:
- Robert C Gallo Distinguished Professorship in Translational Medicine: George Lewis, PhD
- Charles Gordon Smith Professorship in HIV Research: Lishan Su, PhD
- Homer and Martha Gudelsky Distinguished Professorship in Medicine: Manhattan, Charurat PhD
The John C. Martin Foundation endowment is yet another example of the recognition of IHV as one of the leading institutions in virology globally.
The recent signing ceremony was attended by distinguished UMB leaders including: UM School of Medicine Dean Mark T. Gladwin, MD, Dr. Kottilil, MD, PhD, Sarah Kattakuzhy, MD, and Elana Rosenthal, MD, Director of the Institute for Genome Sciences The presence of these esteemed faculty members highlighted the academic and scientific strength that the John C Martin Lectureship and Distinguished Chair will continue to cultivate.
“Dr. John C. Martin’s endowment represents a pivotal advancement in our pursuit of translational virology,” said Dean Gladwin. “By establishing the John C. Martin Distinguished Chair, we are investing in the scientific infrastructure needed to accelerate the translation of molecular discoveries into real-world interventions that combat viral diseases globally. This support will catalyze high-impact research, foster interdisciplinary collaboration, and strengthen our capacity to train future leaders in virology.”
Contact
Jennifer Gonzales
Jennifer.Gonzales@ihv.umaryland.edu
Related stories
Tuesday, March 28, 2023
Two-Time Lasker Awardee and Internationally Acclaimed Virologist, Robert C. Gallo, MD, To Step Down as Director of UM School of Medicine’s Institute of Human Virology (IHV)
Robert C. Gallo, MD, one of the world’s leading virologists and cancer researchers, announced he has stepped down from his position as Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), effective March 24.
Wednesday, November 09, 2022
Lishan Su, PhD, Invested as the UMSOM Charles Gordon Smith Endowed Professor for HIV Research
With his 92-year-old mother watching via live stream from the city of Qingdao, China, and an in-person audience of friends and colleagues gathered in Westminster Hall, Lishan Su, PhD, an internationally prominent virologist and immunologist at the University of Maryland School of Medicine’s (UMSOM) Institute of Human Virology (IHV), was invested as the Charles Gordon Smith Endowed Professor for HIV Research. Dr. Su is a Professor in the Departments of Pharmacology and Microbiology & Immunology at UMSOM’s IHV, who also serves as the Director of the Division of Virology, Pathogenesis, and Cancer at the Institute.
Monday, October 31, 2022
NCI Grants Awarded to IHV to Prevent Cancer and Improve Screening in Sub-Saharan Africa
Institute of Human Virology (IHV) researchers at the University of Maryland School of Medicine (UMSOM) have received two five-year awards from the National Institutes of Health’s National Cancer Institute (NCI) for a total of $7.5 million. One award aims to reduce the incidence of lung cancer and other cancers associated with using tobacco in Botswana. The other is focusing on improving screening and treatment of anal precancer in Nigeria. Both grants will make use of existing HIV treatment and prevention infrastructure in low- and middle-income countries to reach people living with HIV who are most at risk for these particular types of cancers.
Wednesday, December 01, 2021
$6.5M Grant Awarded to Develop Treatment for Alcoholic Liver Disease-Associated Kidney Dysfunction
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and MitoPower LLC (“MitoPower”) were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institute on Alcohol Abuse and Alcoholism. The funds will support the development of MitoPower’s lead compound, MP-04, for the treatment of kidney dysfunction due to alcoholic liver disease, a condition known as alcoholic liver disease-associated hepatorenal syndrome (HRS). The IHV, a Center of Excellence member of the Global Virus Network (GVN), will conduct first-in-human single and multiple ascending dose studies to test the safety of the compound, followed by a Phase 1b study in patients.
Thursday, March 21, 2019
IHV Experts Researching Experimental Drug to Curb Opioid Cravings
Researchers at the University of Maryland School of Medicine (UMSOM) Institute of Human Virology (IHV) are collaborating with scientists at the National Institutes of Health to test an experimental drug to curb opioid cravings.
Tuesday, December 04, 2018
Institute of Human Virology Researchers Discover That a Bacterial Protein Promotes Cancer
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) announced today the discovery that DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell’s ability to respond to and repair DNA damage, a known origin of cancer.
Wednesday, September 19, 2018
Institute of Human Virology (IHV) Awarded $12M to Combat Opioid Epidemic Through Clinical Research Trials
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine will lead a $12 million dollar project to improve the morbidity and mortality of people with opioid use disorder (OUD). Utilizing a novel compound, IHV researches will implement a series of investigations, entitled SEARCH, to evaluate the underlying mechanisms of craving reduction as a strategy to prevent opioid misuse, dependence, and relapse. The grant is awarded through the National Institutes of Health’s (NIH) Helping to End Addiction Long-term (HEAL) Initiative, made possible through groundbreaking funding from the U.S. Congress.
Wednesday, March 21, 2018
Dr. Robert Redfield, Co-Founder of the Institute of Human Virology at the University of Maryland School of Medicine, to Become CDC Director
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) congratulates its co-founder and associate director, Robert R. Redfield, MD, on his appointment to be the next director of the U.S. Centers for Disease Control and Prevention (CDC).
Tuesday, March 20, 2018
UMSOM Cancer Expert at Institute of Human Virology Named Fellow of American Society of Clinical Oncology
Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS, Associate Director of Population Science at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMSOM), and Professor of Epidemiology and Public Health, Institute of Human Virology, has been named a 2018 Fellow of the American Society of Clinical Oncology (ASCO).
Tuesday, November 22, 2016
IHV Awarded $138M to combat HIV/AIDS in Africa & Launches Center for International Health, Education, & Biosecurity
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today more than $138 million in multiple five-year grants awarded by the Centers for Disease Control and Prevention to combat HIV/AIDS in Kenya, Tanzania, Zambia, and Nigeria. The Institute concurrently announced the formation of the IHV Center for International Health, Education, & Biosecurity (CIHEB), and its newly appointed director, Deus Bazira Mubangizi, DrPH, MBA, MPH, Assistant Professor of Medicine, Director, Center for Health, Education, & Biosecurity, Institute of Human Virology, University of Maryland School of Medicine.
Wednesday, April 13, 2016
IHV Releases Data Supporting Community-Based Treatment Providers in Fight Against Hepatitis C
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine released data today at The International Liver Congress 2016 in Barcelona, Spain demonstrating that treatment for hepatitis C virus (HCV) can be provided safely and effectively within a community-based and non-specialist setting.